AMEDISYS INC: debt financing — Amedisys Q1 revenue $594.8M, adj EPS $1.25 vs $1.03 YoY; credit facility extended

AMEDISYS INC

2025-Q1 EPS reported $1.84 revenue$594,781,000

Net service revenue $594.8M (+$23.4M YoY); net income $61.0M ($1.84 diluted) vs $14.4M ($0.44).
Adjusted EBITDA $68.8M vs $59.9M; adjusted net income $41.6M ($1.25 diluted) vs $33.9M ($1.03).
Results include $48.1M gain on equity method investment and $16.8M merger-related expenses.
Fourth Amendment to credit agreement extends maturity to July 30, 2027 and adds Outbound Investment Rules.

item 1.01 item 2.02 item 2.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

AMEDISYS INC amended credit facility of $1.0 billion with Bank of America, N.A. maturing July 30, 2027.

Instrument: credit facility
Principal: $1.0 billion
Counterparty: Bank of America, N.A.
Maturity: July 30, 2027
Event: amendment

Exact text from the filing

as of March 10, 2023 (the “Existing Credit Agreement”). The Existing Credit Agreement provides for a senior secured credit facility in an aggregate principal amount of up to $1.0 billion, which includes a $550.0 million Revolving Credit Facility (the “Revolving Credit Facility”), and a term loan facility with a principal amount of up to $450.0 million (the “Term

View on SEC.gov

Browse all debt financings →

Source: SEC EDGAR

accession 0000896262-25-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.